13D·WATCH Activist + Insider Intelligence Live feed Blog About Pricing
SCHEDULE Filed 2025-06-20 Event 2025-06-17 SEC 0001213900-25-056261 →

Jordan Blair 180 Life Sciences Corp. FRMM

Stake: 31.70% Shares: 1,900,812 CUSIP: 68236V302 Class: Common Stock, $0.0001 par value per share

Item 4 — Purpose of Transaction

The information set forth in Item 3 is hereby incorporated by reference into this Item 4. The Reporting Person acquired the securities for investment purposes. In the future, depending on general market and economic conditions affecting the Issuer and other relevant factors, the Reporting Person may purchase additional securities of the Issuer or dispose of some or all of the securities he currently owns from time to time in open market transactions, private transactions or otherwise. The Reporting Person may also acquire additional shares of common stock under various employee benefit and compensation arrangements with the Company in the future. The Reporting Person does not currently have any plans or proposals which relate to or would result in the following described: (a) The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (b) An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (e) Any material change in the present capitalization or dividend policy of the Issuer; (f) Any other material change in the Issuer's business or corporate structure, including but not limited to, if the Issuer is a registered closed-end investment company, any plans or proposals to make any changes in its investment policy for which a vote is required by section 13 of the Investment Company Act of 1940; (g) Changes in the Issuer's charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person; (h) Causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (i) A class of equity securities of the Issuer becoming eligible for termination of registration pursuant to section 12(g)(4) of the Act; or (j) Any action similar to any of those enumerated above. The Reporting Person retains the right to change his investment intent, and may, from time to time, acquire additional shares of Common Stock or other securities of the Company, or sell or otherwise dispose of (or enter into a plan or arrangements to sell or otherwise dispose of), all or part of the shares of Common Stock or other securities of the Company, if any, beneficially owned by him, in any manner permitted by law. However, the Reporting Person, in his capacity as a member of the Board and Chief Executive Officer may, from time to time, become aware of, initiate, and/or be involved in discussions that relate to the transactions described in this Item 4 and thus retains his right to modify his plans with respect to the transactions described in this Item 4 to acquire or dispose of securities of the Company and to formulate plans and proposals that could result in the occurrence of any such events, subject to applicable laws and regulations.

Cross-References

Insider Activity (last 365d)
36 transactions
18 buys · 3 sales · 7 awards/exercises
Issuer Cluster
5 13D/G filings on this issuer
4 other filings besides this one
Filer Track Record
1 filings by this filer
0 other filings in the data moat
Short Interest · settle 2026-07-15
DTC 5.64
2,663,304 shares short · -13.9% vs prior

Post-Filing Returns · since 2025-06-17 on FRMM

+1 day
0.0%
+5 days
0.0%
+30 days
0.0%
+60 days
0.0%
+90 days
0.0%
+180 days
0.0%

Anchor price 5.70 on closest trading day on/after 2025-06-17. Source: Yahoo Finance daily adj_close (split + dividend adjusted).

Form 4 Insider Transactions · last 365d

DateInsiderRoleTypeSharesPriceValue
2026-04-02 Dalton Angela director Award 203,562
2026-04-02 Edwards Michael A director Award 203,562
2026-04-02 SUCKLING ANDREW P director Award 241,918
2026-04-02 Smith Ryan Lewis director Award 241,918
2026-04-02 Saunders John Tazewell officer Award 358,592
2026-04-02 Rudisill McAndrew director, officer Award 1,884,979
2026-04-02 New Jason Griffin director Award 241,918
2026-04-02 Heter Crystal Jane director Award 241,918
2026-02-18 Smith Ryan Lewis director J 16,718
2025-12-01 Smith Ryan Lewis director Gift 16,718
2025-11-14 New Jason Griffin director Gift 218,456
2025-11-14 Smith Ryan Lewis director Gift 267,137
2025-11-14 SUCKLING ANDREW P director Gift 149,020
2025-11-14 Heter Crystal Jane director Gift 182,742
2025-11-14 Rudisill McAndrew director, officer Gift 410,865
2025-11-14 Rudisill McAndrew director, officer Gift 370,000
2025-11-12 Saunders John Tazewell officer Award 109,312
2025-11-12 Rudisill McAndrew director, officer Award 1,365,000
2025-11-12 Heter Crystal Jane director Award 649,748
2025-11-12 SUCKLING ANDREW P director Award 649,748
2025-11-12 Smith Ryan Lewis director Award 887,500
2025-11-12 New Jason Griffin director Award 952,500
2025-11-12 New Jason Griffin director F 257,794
2025-11-12 Smith Ryan Lewis director F 176,613
2025-11-12 SUCKLING ANDREW P director F 175,854
Showing 25 of 36

Other 13D/G Filings on 180 Life Sciences Corp.

FiledFormFilerStakeShares
2025-08-18 SCHEDULE Goodman Anthony Brian 1,320,000 view →
2025-04-11 SCHEDULE ELRAY RESOURCES, INC. 52.80% 4,318,000 view →
2021-12-13 SC Feldmann Marc view →
2020-11-16 SC KBL IV SPONSOR LLC view →

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. From $49/mo.

See pricing →